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Symptomatic paroxysmal hypertension without significantly elevated catecholamine 
concentrations and with no evidence of an underlying adrenal tumor is known as 
pseudopheochromocytoma.  
Methods 
We describe the case of a female patient with paroxysmal hypertensive crises accompanied by 
headache, vertigo, tachycardia, nausea and altered mental status. Previously she was treated 
for a longer period with alprazolam due to panic disorder. Causes of secondary hypertension 
were excluded. Neurological triggers (intracranial tumor, cerebral vascular lesions, 
hemorrhage, and epilepsy) could not be detected.  
Results 
Setting of the diagnosis of pseudopheochromocytoma treatment was initiated with alpha- and 
beta-blockers resulting in less common occurrence of the symptoms. Alprazolam was 
restarted at a daily dose of 1 mg. Patient’s clinical condition improved rapidly and the dosage 
of alpha and beta blockers could be decreased. 
Conclusions 
We conclude that the withdrawal of an anxiolytic therapeutic regimen may generate 
sympathetic overdrive resulting in life threatening paroxysmal malignant hypertension and 
secondary encephalopathy. We emphasize that pseudopheochromocytoma can be diagnosed 
only after exclusion of the secondary causes of hypertension. We highlight the importance of 
psychopharmacological approach to this clinical entity. 
 





Pseudopheochromocytoma is a rapid onset bunch of symptoms generated by sympathoadrenal 
overdrive [1, 2]. In most of the cases this clinical syndrome includes paroxysmal (malignant) 
hypertension, tremor, palpitation, sweating, chest pain, headache, nausea, dizziness, and 
pseudoseizures [3–5]. The episodes of clinical symptoms and complaints may last from 
minutes up to hours. Importantly, the basic difference between pheochromocytoma and 
pseudopheochromocytoma is that in the latter no biochemical and anatomical background can 
be clarified, however evidence of mild to moderate catecholamine release may be proven 
during any of the paroxysms [6–9]. It has been suggested that a number of factors interact 
leading to the development of this clinical condition in any one individual (Table 1.). 
Furthermore, there are differences in the severity and clinical characteristics between patients 
that may result in the diversity of pseudopheochromocytoma [10]. Interestingly, besides the 
already known clinical causes psychological childhood traumas may also play a role in the 
genesis of this clinical entity, where psychotherapy can effectively relieve symptoms [11]. 
Furthermore, it has to be emphasized that this condition may be secondary to certain drug 
therapies (e.g., sympathomimetic agents, tricyclic antidepressants, or reboxetine) all of which 
can contribute to the appearance of sympathetic overdrive [12–14]. However, it has not been 
clearly elucidated whether the modification or the termination of a former 
psychopharmacological therapy may be able to generate such severe symptoms leading to the 
diagnosis of pseudopheochromocytoma [15]. Throughout our work we aimed to clarify the 
role of the withdrawal of the anxiolytic drug, alprazolam, in the genesis of the characteristic 




In January 2014, a 55-year-old Caucasian woman was admitted to our Emergency Unit with 
paroxysmal malignant hypertension accompanied by headache, vertigo, tachycardia, 
lacrimation, nausea and altered mental status. Her medical history included a caesarean 
section (1984), an abdominal surgery due to mechanical ileus, a laparoscopic cholecystectomy 
(1995), a gastro-oesophageal reflux and a total thyroidectomy due to a benign non-toxic 
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multi-nodular goitre, later requiring thyroid hormonal substitution. In 2008, an elevated 
fasting glucose level pointed to an underlying type 2 diabetes mellitus. Hypertension and 
sinus tachycardia was first diagnosed in 2003. Consequently, the patient underwent several 
examinations in various hospitals but no underlying organic causes of her complaints could be 
detected. Endocrinological disorders - especially pheochromocytoma – were excluded on 
several occasions. The altered mental status during the hypertensive crises raised the 
possibility of neurological deficiency, but no signs of intracranial tumor, cerebral vascular 
lesions, hemorrhage or even epilepsy were detectable. Moreover, cardiac arrhythmias and 
ischemic heart disease were also excluded. Eventually, in 2004, after numerous diagnostic 
procedures panic syndrome was diagnosed, therefore anxiolytic and antidepressant 
medications were initiated. Between 2004 and 2013 the patient was treated with this 
combination of psychopharmacological agents. During a thorough psychiatric follow-up 
period the frequency of the paroxysms dropped noticeably, but the patient seemed to be 
addicted to the psychopharmacological regimen so the medications were withdrawn in 
another center. During the following year the patient did not show any clinical symptoms of 
paroxysmal hypertension. At the time of the current admission to our clinic the patient’s 
medical therapy consisted of metoprolol 100 mg twice daily, esomeprazole 40 mg daily, 
levothyroxin 100 µg daily, allopurinol 100 mg daily, and insulin therapy (glulisine insulin 
three-times a day and glargine insulin once a day).  
The patient presented herself at the Division of Rare Diseases for further etiologic 
examinations. During the first clinical evaluation a really severe attack could be observed. 
The patient became unconscious, her blood pressure rapidly rose to 230/100 mmHg, with a 
regular heart rate of 160-180/min (Figure 1). Moreover, focal muscle twitching appeared on 
her left face, and excessive lacrimation and flushing could also be observed. Because of her 
unstable clinical condition she was immediately admitted to our Intensive Care Unit. Before 
the administration of additional medications the patient severe clinical condition improved 
significantly on its own. By the end of the paroxysm the frequency of sinus rhythm decreased 
to 90/min and the blood pressure was also normalized. After the crisis, no signs of arrhythmia, 
or long standing neurological defects could be observed. No other significant clinical 
abnormalities could be found during further clinical examinations. Afterwards during the first 
week of hospitalisation she had attacks 2-4 times a day. These paroxysmal hypertensive crises 
lasted for 3-5 minutes and then disappeared spontaneously without any medical interventions. 
Between the paroxysms the patient did not have any complaints. Because of the repeated 
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attacks a combination of alpha- and beta-adrenoceptor blockers was given, which was able to 
lower the blood pressure and the heart rate during the paroxysms, but not the frequency of the 
attacks. Holter electrocardiography recordings and 12-lead surface electrocardiograms 
revealed sudden onset episodes of sinus tachycardia without any signs of further atrial or 
ventricular arrhythmias (Figure 2.). Renal Doppler ultrasound examination was performed to 
exclude renovascular disease. It revealed physiological blood flow in both renal arteries, with 
no significant difference regarding resistive indices (0.67 vs. 0.7, respectively). Although 
previous examinations were not able to prove any endocrinological background of the 
paroxysms, a repeated laboratory testing of pheochromocytoma and carcinoid was performed. 
Laboratory results of our patient are shown in Table 2. An elevated serum chromogranin A 
level appeared, but it proved to be a false positive result due to a concomitant proton-pump 
inhibitor (PPI) therapy (after the removal of PPI, chromogranin level was in the normal 
range). Surprisingly, an adenoma could be detected in the left adrenal gland during computed 
tomography. Due to the repeated severe clinical symptoms we were obliged to start the 
treatment of the pheochromocytoma, thus, a cardio-selective beta-blocker (bisoprolol 5 mg 
twice daily) in combination with an alpha-adrenoceptor-blocker (doxazosine 4 mg once daily) 
were initiated. During this time, urine concentrations of 5-hydroxyindoleacetic acid (5-
HIAA), metanephrine, normetanephrine and dopamine were found to be normal. Although, 
we measured slightly elevated serum concentrations of noradrenalin and dopamine during an 
attack, the levels did not fulfill the criteria for pheochromocytoma (Table 3.). To ensure the 
safe exclusion of pheochromocytoma, a 131I-MIBG scan was also performed, which did not 
reveal any abnormalities relating to adrenal gland dysfunction (Figure 3). Furthermore, 
hyperaldosteronism as a very rare cause of paroxysmal hypertension could also be excluded. 
Further laboratory tests helped to exclude any hormonal abnormalities, so the aforementioned 
adrenal gland adenoma was regarded as an incidentaloma. Thyroid laboratory tests showed 
the effective hormonal substitution of hypothyroidism secondary to the previous 
thyroidectomy. After excluding the chances of endocrine disorders we focused on anxiolytic 
medication. For this reason psychiatric examination was performed and alprazolam was re-
administered in a daily dose of 1 mg (0.5 mg twice daily). We could demonstrate an 
immediate clinical improvement, furthermore, the daily dose of alpha and beta-blockers could 
also be decreased. During the administration of alprazolam in a daily dose of 1 mg sleepiness, 
fatigue occurred, therefore we decreased the daily dose to 0.5 mg. Consequently the 
paroxysmal increase in blood pressure reappeared so further therapy of 1 mg was necessary to 
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maintain. After a four-week period at the Intensive Care Unit the patient was discharged 
though still with mild symptoms and with an improved quality of life. The systolic and 
diastolic blood pressure and heart rate collected after the discharge of our patient were 





The clinical constellation of paroxysmal hypertension without a clear underlying cause and 
without proof of pheochromocytoma has been introduced as pseudopheochromocytoma, 
which may lead to severe disability and a worsening quality of life. Importantly, this clinical 
entity is characterized by paroxysmal episodes of serious hypertension and concomitant 
symptoms due to sympathoadrenal overdrive, which are not related to emotional stress [16]. 
However, some patients may experience anxiety but only in reaction to the distressing 
symptoms and complaints. On the other hand, panic disorder is characterized by mild blood 
pressure elevation where panic and fear are inevitably discoverable [17]. Despite the different 
provoking mechanisms these clinical entities bear resemblance to each other. Unfortunately, 
in the case of lacking emotional distress, paroxysmal hypertension is usually thought to be an 
unexplained disorder [1]. Numerous clinical conditions may manifest as paroxysmal 
hypertension and should be clarified where clinically appropriate. Paroxysmal hypertension is 
mostly accompanied by tachycardia (palpitation) where the activation of sympathoadrenal 
system is likely to be the underlying factor. Previously, it has been shown that patients with 
pseudopheochromocytoma show beta and alpha-1-adrenoceptor hypersensitivity [6]. The 
effective response to alpha and beta blockers also seem to support this hypothesis. However, 
in some circumstances these drugs are not effective in the control of the symptoms [18]. In 
these particular cases psychopharmacological therapeutic approach may be useful in the 
prevention of the paroxysms and restoring quality of life [19]. Previously, antidepressant 
agents (desipramine, paroxetine) in combination with anxiolytic drugs and psychotherapeutic 
interventions have been shown to be effective in the prevention and elimination of the attacks 
[18]. Importantly, the aforementioned management strategy may be able to control the clinical 
symptoms but the disease itself is never eradicated. Moreover, it is important to note that 
paroxysmal hypertension and the concomitant symptoms may be secondary to drug therapy 
which may raise sympathetic activity. It has not been established whether the withdrawal of 
an anxiolytic therapy may be able to result in such serious consequences. Benzodiazepines 
(e.g. alprazolam) are known for their anxiolytic, sedative, hypnotic, euphoric, anticonvulsant, 
and muscle relaxant effects while acting on gamma-aminobutyric acid A (GABAA) receptors. 
The GABAA is an ionotropic receptor and ligand-gated chloride ion channel. Its endogenous 
ligand is GABA, which is an inhibitory neurotransmitter in the central nervous system. 
Furthermore, it has been shown that neuronal cholecystokinin (CCK) receptors are also 
implicated in these mechanisms [20]. The CCK receptor activation has been proven to be 
responsible for controlling fear and panic attacks. Consequently, the withdrawal of the 
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benzodiazepines unarguably can lead to the liberation of CCK receptors from their inhibition. 
(Figure 4.) The concomitant chance for panic attacks are increased, moreover alterations in 
vascular tone, sudden increase in blood pressure and life threatening hypertensive 
encephalopathy are considerable sequels [21, 22].  
In our work we described the medical history of a female patient who was treated with the 
anxiolytic drug alprazolam for years, due to panic disorder. Lately, the anxiolytic therapy was 
terminated since symptoms had improved and because the danger of addiction was 
considerable. Recently, our patient was admitted to our center due to episodes of severe, 
paroxysmal hypertension with accompanying symptoms reflecting increased sympathetic 
tone. Importantly, these clinical signs were not initiated by fear or emotional stress. After 
ruling out all potential secondary underlying causes that may have contributed to the 
worsening of the clinical status, diagnosis of pseudopheochromocytoma was established. 
Considering the patient’s severe symptoms alpha and beta-adrenoceptor blocker treatment 
were introduced, which have not been effective enough in the prevention of further 
paroxysms. It was realized that the cessation of alprazolam treatment might be responsible for 
the sudden worsening of the clinical condition. Thus, alprazolam therapy was restarted 
resulting in a rapid improvement of the symptoms and quality of life. The reappearance of 
elevated blood pressure secondary to the temporary decrease in the daily dose of alprazolam 
is considered to be a positive challenge test. 
To our best knowledge this is the first paper to report the possible role of anxiolytic 
withdrawal in the genesis of pseudopheochromocytoma. Therefore, we emphasize that the 
termination of an anxiolytic therapeutic regimen may generate severe sympathetic 
overshooting resulting in life threatening paroxysmal malignant hypertension and secondary 
encephalopathy. We accentuate that pseudopheochromocytoma can be diagnosed only after 
the exclusion of secondary causes of hypertension. Importantly, pheochromocytoma has to be 
safely ruled out. Besides the administration of alpha and beta blockers, we stress the 
importance of psychopharmacological and psychotherapeutic approach to this clinical entity. 
 
List of abbreviations 
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Table 1. Various clinical conditions can present in a similar way to 
pseudopheochromocytoma. Importantly, certain drug therapies can contribute to the 
appearance of pseudopheochromocytoma-like symptoms. 
 
Endocrine hyperthyroidism, carcinoid, mastocytosis, hypoglycemia, insulinoma, 
menopausal syndrome, adrenal medullary hyperplasia, reninoma 
Pharmacologic tricyclic antidepressants, monoamine oxidase inhibitors, cocaine, alcohol 
withdrawal, abrupt clonidine withdrawal 
Cardiovascular ischemic heart disease, arrhythmias, baroreflex failure, renovascular 
disease, postural orthostatic tachycardia syndrome 
Neurologic migraine headache, cluster headache, stroke, diencephalic autonomic 
epilepsy, meningioma 
Other preeclampsia or eclampsia, obstructive sleep apnea, anxiety or panic 




Table 2. Laboratory data of the patient 
GFR: glomerular filtration rate, EPI: epidemiology collaboration, HgbA1c: Hemoglobin A1c, AST: Aspartate 
transaminase, ALT: Alanine transaminase, LDH: lactate dehydrogenase, CRP: C reactive protein, WBC: white 
blood cell, RBC red blood cell, MCV: mean corpuscular volume, MCH: mean corpuscular hemoglobin 
Laboratory variables Results Laboratory references 
  Na
+
 144 133-146 mmol/L 
  K
+
 4.2 3.5-5.3 mmol/L 
  Cl
-
 107 99-111 mmol/L 
  Ca (total) 2.33 2.1-2.6 mmol/L 
  Blood urea nitrogene 4.2 3.6-7.2 mmol/L 
  Creatinine 66 44-97 µmol/L 
  eGFR (EPI) 89 >90 mL/min/1.73 m2 
  Glucose 6 3.6-6.0 mmol/L 
  HgbA1C 7.8 4.2-6.1 % 
  Albumin 42 35-52 g/L 
  Total protein 63 60-80 g/L 
  AST 26 <40 U/L 
  ALT 38 <40 U/L 
  LDH 194 135-220 U/L 
  Alkaline phosphatase 74 40-115 U/L 
  Amylase 23 <100 U/L 
  Lipase 17 <70 U/L 
  CRP 1.9 <4.6 mg/L 
  WBC 8.66 4.8-10.8 Giga/L 
  RBC 3.97 4.2-5.4 Tera/L 
  Hemoglobin 123 115-150 g/L 
  Hematocrite 0.35 0.35-0.47 
  Platelet 277 150-400 Giga/L 
  MCV 88.9 80-99 fL 




Table 3. Hormone levels of the studied patient 
ACTH. Adrenocorticotrop hormone, PPI: proton-pump inhibitor, 5-HIAA: 5-hydroxyindoleacetic acid 
Hormonal variables Results Laboratory references 
Plasma samples 
  Thyroid stimulating hormone 2.3 0.3-4.2 mU/L 
  ACTH (8h) <19 <75 ng/L 
  Cortisol 245.8 138-690 nmol/L 
  Plasma rennin non detectable 0.5-1.9 x hrs   ug/L 
  Plasma aldosterone 54.1 28-291 pmol/l 
  Chromogranin A (with PPI) 875.4 20-100 µg/L 
  Chromogranin A (without PPI) 48.3 20-100 µg/L 
Plasma samples during paroxysm 
  Adrenaline  0.32 <0.41 nmol/L 
  Noradrenaline 3.37 0.37-2.6 nmol/L 
  Dopamine 2.73 <0.88 nmol/L 
Urine samples (24-hour collection) 
  Adrenaline  16 3-109 nmol/die 
  Noradrenaline 187 89-473 nmol/die 
  Dopamine 2171 424-1612 nmol/die 
  Homovanillic acid 31 9.1-33.8 µmol/die 
  Vanillyl mandelic acid 31 <34 µmol/die 
  5-HIAA 23 3.7-42.9 µmol/die 
  Metanephrines 356 375-1506 nmol/die 
  Normetanephrines 1340 573-1932 nmol/die 












Table 4. Data on blood pressure and heart rate obtained after the discharge of our patient 
revealed the lack of reoccurrence of the paroxysms. BP: blood pressure, sys: systolic, dia: 
diastolic 
 
 Maximum Minimum Mean 
BP sys (mmHg) 145 133 140 
BP dia (mmHg) 85 79 82 





Figure 1. During the first clinical evaluation of the patient a really severe attack could be 
observed. The patient became unconscious, her systolic blood pressure rapidly rose above 230 
mmHg. Similar trends were observed during the repeated paroxysms. 
BP: Blood pressure 
 
Figure 2. Holter electrocardiogram revealed a paroxysmal sinus tachycardia during the attack. 
No other atrial arrhythmias or life threatening ventricular arrhythmias (ventricular tachycardia 
and fibrillation) were observed. 
 
Figure 3. For I-131 MIBG acquisition 40 MBq radiopharmaceutical was injected. A whole 
body (4cm/min) and abdominal SPECT/CT acquisition were performed on MEDISO 
AnyScan SC system 72 hours after the injection. SPECT parameters were: 1 min/projection, 
64 views, matrix size 64x64. A 16-slice CT was used, with 120 mAS and 120 kV abdominal 
filter. For the SPECT reconstruction OSEM method was performed. None of the adrenal 
regions showed abnormal focal uptake.  
 
MIBG: Metaiodobenzylguanidine, SPECT: Single-Photon Emission Computed Tomography, CT: 
Computed Tomography, OSEM: Ordered Subset Expectation Maximization 
 
 
Figure 4. The effects of benzodiazepines on GABA (gamma-aminobutyric acid) receptor and 
cholecystokinin (CCK) are shown. On one hand binding of GABA molecules to their sites 
triggers the opening of a chloride ion-selective pore resulting in the hyperpolarization of the 
cell. On the other hand benzodiazepines are likely to antagonize the cholecystokinin-induced 
activation of neurons.  
 
